349 related articles for article (PubMed ID: 20844004)
1. Neutral antibodies to the TSH receptor are present in Graves' disease and regulate selective signaling cascades.
Morshed SA; Ando T; Latif R; Davies TF
Endocrinology; 2010 Nov; 151(11):5537-49. PubMed ID: 20844004
[TBL] [Abstract][Full Text] [Related]
2. How one TSH receptor antibody induces thyrocyte proliferation while another induces apoptosis.
Morshed SA; Ma R; Latif R; Davies TF
J Autoimmun; 2013 Dec; 47():17-24. PubMed ID: 23958398
[TBL] [Abstract][Full Text] [Related]
3. Characterization of thyrotropin receptor antibody-induced signaling cascades.
Morshed SA; Latif R; Davies TF
Endocrinology; 2009 Jan; 150(1):519-29. PubMed ID: 18719020
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the phosphatidylinositol 3-kinase, Akt/protein kinase B, FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1 signaling pathways by thyroid-stimulating hormone (TSH) and stimulating type TSH receptor antibodies in the thyroid gland.
Suh JM; Song JH; Kim DW; Kim H; Chung HK; Hwang JH; Kim JM; Hwang ES; Chung J; Han JH; Cho BY; Ro HK; Shong M
J Biol Chem; 2003 Jun; 278(24):21960-71. PubMed ID: 12668683
[TBL] [Abstract][Full Text] [Related]
5. TSH receptor autoantibodies.
Michalek K; Morshed SA; Latif R; Davies TF
Autoimmun Rev; 2009 Dec; 9(2):113-6. PubMed ID: 19332151
[TBL] [Abstract][Full Text] [Related]
6. TSH receptor antibodies do not alter the function of gonadotropin receptors stably expressed in eukaryotic cells.
Tonacchera M; Ferrarini E; Dimida A; Agretti P; De Marco G; De Servi M; Chiovato L; Cetani F; Vitti P; Pinchera A
Eur J Endocrinol; 2004 Mar; 150(3):381-7. PubMed ID: 15012625
[TBL] [Abstract][Full Text] [Related]
7. The effect of thyrotropin-receptor blocking antibodies on stimulating autoantibodies from patients with Graves' disease.
Lenzner C; Morgenthaler NG
Thyroid; 2003 Dec; 13(12):1153-61. PubMed ID: 14751037
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal pathogenic antibodies to the thyroid-stimulating hormone receptor in Graves' disease with potent thyroid-stimulating activity but differential blocking activity activate multiple signaling pathways.
Gilbert JA; Gianoukakis AG; Salehi S; Moorhead J; Rao PV; Khan MZ; McGregor AM; Smith TJ; Banga JP
J Immunol; 2006 Apr; 176(8):5084-92. PubMed ID: 16585606
[TBL] [Abstract][Full Text] [Related]
9. Biased signaling by thyroid-stimulating hormone receptor-specific antibodies determines thyrocyte survival in autoimmunity.
Morshed SA; Ma R; Latif R; Davies TF
Sci Signal; 2018 Jan; 11(514):. PubMed ID: 29363585
[TBL] [Abstract][Full Text] [Related]
10. Graves' Disease Mechanisms: The Role of Stimulating, Blocking, and Cleavage Region TSH Receptor Antibodies.
Morshed SA; Davies TF
Horm Metab Res; 2015 Sep; 47(10):727-34. PubMed ID: 26361259
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies to the thyrotropin receptor.
Ando T; Davies TF
Clin Dev Immunol; 2005 Jun; 12(2):137-43. PubMed ID: 16050145
[TBL] [Abstract][Full Text] [Related]
12. Rescue of thyroid cells from antibody induced cell death via induction of autophagy.
Morshed S; Latif R; Davies TF
J Autoimmun; 2022 Jan; 126():102746. PubMed ID: 34801870
[TBL] [Abstract][Full Text] [Related]
13. Critical Differences between Induced and Spontaneous Mouse Models of Graves' Disease with Implications for Antigen-Specific Immunotherapy in Humans.
Rapoport B; Banuelos B; Aliesky HA; Hartwig Trier N; McLachlan SM
J Immunol; 2016 Dec; 197(12):4560-4568. PubMed ID: 27913646
[TBL] [Abstract][Full Text] [Related]
14. Signal responses to neutral TSH receptor antibody - A cycle of damage in the pathophysiology of Graves' disease.
Morshed S; Latif R; Davies TF
J Autoimmun; 2023 Apr; 136():103012. PubMed ID: 36898184
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous assay for three types of thyrotropin receptor antibody activities using FRTL-5 cells in patients with autoimmune thyroid diseases.
Zhu Y; Portmann L; Dénéréaz N; Lemarchand-Béraud T
Eur J Endocrinol; 1994 Oct; 131(4):359-68. PubMed ID: 7921224
[TBL] [Abstract][Full Text] [Related]
16. A new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor.
Neumann S; Eliseeva E; McCoy JG; Napolitano G; Giuliani C; Monaco F; Huang W; Gershengorn MC
J Clin Endocrinol Metab; 2011 Feb; 96(2):548-54. PubMed ID: 21123444
[TBL] [Abstract][Full Text] [Related]
17. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.
Tsui S; Naik V; Hoa N; Hwang CJ; Afifiyan NF; Sinha Hikim A; Gianoukakis AG; Douglas RS; Smith TJ
J Immunol; 2008 Sep; 181(6):4397-405. PubMed ID: 18768899
[TBL] [Abstract][Full Text] [Related]
18. Thyroid-stimulating monoclonal antibodies.
Sanders J; Jeffreys J; Depraetere H; Richards T; Evans M; Kiddie A; Brereton K; Groenen M; Oda Y; Furmaniak J; Rees Smith B
Thyroid; 2002 Dec; 12(12):1043-50. PubMed ID: 12593717
[TBL] [Abstract][Full Text] [Related]
19. Thyrotropin (TSH) receptor antibodies (TSHrAb) can inhibit TSH-mediated cyclic adenosine 3',5'- monophosphate production in thyroid cells by either blocking TSH binding or affecting a step subsequent to TSH binding.
Dallas JS; Cunningham SJ; Patibandla SA; Seetharamaiah GS; Morris JC; Tahara K; Kohn LD; Prabhakar BS
Endocrinology; 1996 Aug; 137(8):3329-39. PubMed ID: 8754759
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of a monoclonal antibody to the thyrotropin receptor that acts as a powerful thyroid-stimulating autoantibody antagonist.
Sanders J; Allen F; Jeffreys J; Bolton J; Richards T; Depraetere H; Nakatake N; Evans M; Kiddie A; Premawardhana LD; Chirgadze DY; Miguel RN; Blundell TL; Furmaniak J; Smith BR
Thyroid; 2005 Jul; 15(7):672-82. PubMed ID: 16053383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
